# Sight Sciences, Inc. (SGHT)

> Source: Nexqual · https://nexqual.com/SGHT · data as of 2026-10-29 20:00 UTC · cite as "Nexqual, Sight Sciences, Inc. (SGHT), nexqual.com/SGHT" · informational, not investment advice.

**Price:** USD 9.57 (+3.57% on the day) · last close of Oct 29, 2026; US market closed, not a live price. Prev close 9.24 · day 9.25–9.63 · 52w 3.38–9.71 · market cap $527M · NMS

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $83.4M, net income -$29.8M (-35.7% margin), free cash flow -$23.3M (SEC filings).
- Insider open-market sales, last ~7 months: 12 Form 4 filings, $1.2M; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Insider open-market purchases, last ~7 months: 1 Form 4 filing, $69K; 1 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 2.13 on a 1–5 scale) (8 analysts), mean target USD 10.17 (range 8–14).
- Total return with dividends: 1Y +81.9% vs S&P 500 +14.8%; 5Y -64.5% vs S&P 500 +79.1%.
- Next earnings: 2026-11-04, EPS estimate USD -0.12, revenue estimate $23.5M. All companies reporting that day: https://nexqual.com/earnings/2026-11-04
- Dividend: SGHT paid no cash dividend in the last five years.
- Short interest: 3.09% of float (as of 2026-10-15), 3.6 days to cover.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $49.0M | $71.3M | $81.1M | $79.9M | $77.4M | $83.4M |
| Gross profit | $40.3M | $59.0M | $69.2M | $68.3M | $66.7M | — |
| Operating income | -$51.5M | -$84.0M | -$57.3M | -$50.5M | -$37.1M | -$27.9M |
| Net income | -$63.0M | -$86.2M | -$55.5M | -$51.5M | -$38.4M | -$29.8M |
| EPS (diluted) | -$2.36 | -$1.80 | -$1.14 | -$1.03 | -$0.74 | — |
| Free cash flow | -$53.4M | -$76.9M | -$48.0M | -$22.7M | -$29.9M | -$23.3M |
| Gross margin | 82.4% | 82.7% | 85.3% | 85.5% | 86.2% | — |
| Operating margin | -105.2% | -117.7% | -70.7% | -63.3% | -48.0% | -33.4% |
| Net margin | -128.6% | -120.9% | -68.5% | -64.5% | -49.7% | -35.7% |
| Revenue growth | +77.1% | +45.7% | +13.6% | -1.5% | -3.1% | — |
| Cash + short-term investments | $261M | $185M | $138M | $120M | $92.0M | — |
| Total debt | $35.0M | $35.0M | $35.0M | $40.0M | $42.4M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 6.3x · EV/Sales 5.9x · P/B 10.0x · FCF yield -4.43% · Earnings yield -5.64% · Net cash $39.0M · EV $488M

## Insider sales (SEC Form 4, open-market, last ~7 months)
12 of 12 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-10-02 | Taylor Brenton | EVP, Operations & R&D | 2,988 | $26K | 1.1% | Yes | Too little history (no open-market trades in 2023 or 2024) |
| 2026-10-02 | Bauerlein Alison | Chief Operating Officer | 25,260 | $224K | 3.8% | Yes | Too little history (no open-market trades in 2023) |
| 2026-10-02 | Rodberg James | Chief Financial Officer | 7,208 | $64K | 3.2% | Yes | Too little history (no open-market trades in 2023 or 2024) |
| 2026-10-01 | Badawi David | Chief Technology Officer | 7,797 | $71K | 0.4% | Yes | Too little history (no open-market trades in 2023) |
| 2026-10-01 | Badawi Paul | President and CEO | 29,653 | $268K | 0.5% | Yes | Too little history (no open-market trades in 2023) |
| 2026-07-06 | Hayden Jeremy B. | Chief Legal Officer | 12,733 | $70K | 3.4% | Yes | Too little history (no open-market trades in 2023) |
| 2026-07-06 | Badawi David | Chief Technology Officer | 7,418 | $41K | 0.4% | Yes | Too little history (no open-market trades in 2023) |
| 2026-07-02 | Rodberg James | Chief Financial Officer | 6,902 | $37K | 3% | Yes | Too little history (no open-market trades in 2023 or 2024) |
| 2026-07-02 | Bauerlein Alison | Chief Operating Officer | 24,184 | $130K | 3.5% | Yes | Too little history (no open-market trades in 2023) |
| 2026-07-01 | Taylor Brenton | EVP, Operations & R&D | 2,829 | $15K | 1.1% | Yes | Too little history (no open-market trades in 2023 or 2024) |
| 2026-07-01 | Badawi Paul | President and CEO | 28,684 | $155K | 0.5% | Yes | Too little history (no open-market trades in 2023) |
| 2026-05-18 | Bauerlein Alison | Chief Operating Officer | 12,728 | $65K | 1.8% | Yes | Too little history (no open-market trades in 2023) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Insider purchases (SEC Form 4, open-market, last ~7 months)
1 purchase, $69K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-06-10 | Encrantz Staffan | Director | 14,100 | $69K | 4.88 | Opportunistic (traded every year 2023–2025, no repeating month) |

## Analysts
Consensus Buy (mean 2.13 on a 1–5 scale), 8 analysts; mean target USD 10.17 (low 8, high 14).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-15 | HC Wainwright & Co. | Initiated | Buy | $14 |
| 2026-10-05 | Citigroup | Target raised | Neutral | $8 → $10 |
| 2026-08-17 | Citigroup | Target raised | Neutral | $6 → $8 |
| 2026-08-06 | UBS | Target raised | Buy | $7 → $8 |
| 2026-07-08 | Citigroup | Target raised | Neutral | $5.15 → $6 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-30) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | +81.9% | -64.5% |
| S&P 500 (SPY) | +14.8% | +79.1% |
| Per year | +82.6% | -18.7% |
| Volatility (annualized) | 75.3% | 90.3% |
| Max drawdown | -61.9% (Dec 2025→Apr 2026) | -94.4% (Oct 2021→Oct 2023) |

## Dividends
SGHT paid no cash dividend in the last five years.

## Short interest
1,241,141 shares sold short, 3.09% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 1,252,772 shares (-0.9%). Days to cover: 3.6 (short shares ÷ average daily volume).

## Peers (Medical Devices)
INSP (Inspire Medical Systems, Inc.) USD 71.18 +0.30% · ESTA (Establishment Labs Holdings Inc) USD 68.41 -0.81% · BFLY (Butterfly Network, Inc.) USD 7.51 -3.84% · UFPT (UFP Technologies, Inc.) USD 293.3 +2.55% · TMDX (TransMedics Group, Inc.) USD 67.12 +0.33% · ALMR (Alamar Biosciences, Inc.) USD 34.04 -0.76%

## More
Full page: https://nexqual.com/SGHT · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)


Other companies that name SGHT in their own reports (relationship from SGHT's side):

| Relationship | Company | Their filing | Sentence |
|---|---|---|---|
| partner | United Acquisition Corp. I (UAC) | 10-K 2026-03-30 | "Berkshire Resources LLC, Standard Industrial Manufacturing Partners LTD, and Sight Sciences, Inc. Mr. Hicks was on the national board" |

## Revenue by business segment (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Surgical Glaucoma | $20.7M | 88.6% | +7.7% |
| Dry Eye | $2.7M | 11.4% | +703.3% |
| Total revenue | $23.4M | 100% | — |

## Company outlook (8-K filed 2026-08-05)

- "Guidance and Reduces Adjusted Operating Expense Guidance MENLO PARK, Calif., August 5, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc."
- "(Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the second quarter ended June 30, 2026, raised its revenue guidance and reduced its adjusted operating expense guidance, both for full year 2026."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.12 | $-0.16 | +$0.04 | $23.5M | 6 |
| Next quarter (ends 2026-12-31) | $-0.13 | $-0.16 | +$0.03 | $23.7M | 6 |
| Current fiscal year (ends 2026-12-31) | $-0.49 | $-0.66 | +$0.16 | $90.3M | 6 |
| Next fiscal year (ends 2027-12-31) | $-0.40 | $-0.53 | +$0.13 | $101.0M | 6 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-11-04): ±25.9%; last 8 reports averaged ±14.9%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 22 | 128.1% | ±25.9% |
| 2027-02-19 | 113 | 60.3% | ±27.2% |
| 2027-05-21 | 204 | 62.7% | ±39.2% |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Aug 5, 2026 | Quarter ended Jun 30, 2026 | −$0.08 | −$0.14 | Beat +42.9% | +25.7% |
| May 6, 2026 | Quarter ended Mar 31, 2026 | −$0.24 | −$0.20 | Miss −20.0% | +22.2% |
| Mar 4, 2026 | Quarter ended Dec 31, 2025 | −$0.08 | −$0.14 | Beat +42.9% | -24.7% |
| Jan 13, 2026 | Quarter ended Dec 31, 2025 | −$0.08 | −$0.14 | Beat +42.9% | -7.0% |
| Nov 6, 2025 | Quarter ended Sep 30, 2025 | −$0.16 | −$0.26 | Beat +38.5% | +15.7% |
| Aug 7, 2025 | — | — | — | — | +15.2% |
| May 8, 2025 | — | — | — | — | +7.7% |
| Mar 5, 2025 | — | — | — | — | +0.8% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

## Recent SEC filings (last 120 days)
| Filed | Form | What it says | Filing |
|---|---|---|---|
| 2026-08-10 | 8-K | Director or executive officer change, or pay arrangement — “Appointment of Chief Legal Officer On August 6, 2026, the Board of Directors (the "Board") of Sight Sciences, Inc. (the "Company") appointed Kashif Rashid to serve as the Company's Chief Legal Officer and Corporate Secretary, effective August 10, 2026. Mr. Rashid, aged 53, previously served as General Counsel of Nevro Corp., a medical device company dedicated to treating chronic pain, from December 2017 to January 2024, and as Senior Vice President, Corporate Development, and Chief Legal Officer from January 2024…” | https://www.sec.gov/Archives/edgar/data/1531177/000119312526341346/0001193125-26-341346-index.htm |
| 2026-08-05 | 10-Q | Quarterly report · period ended Jun 30, 2026 | https://www.sec.gov/Archives/edgar/data/1531177/000119312526335204/0001193125-26-335204-index.htm |
| 2026-08-05 | 8-K | Quarterly results; Regulation FD disclosure | https://www.sec.gov/Archives/edgar/data/1531177/000119312526335092/0001193125-26-335092-index.htm |
Source: SEC EDGAR. Quotes are the opening words of each item as filed.